<?xml version="1.0" encoding="UTF-8"?>
<p>In the last 20 years, SARS and MERS have been found as new infectious agents, emerged to cause epidemics (de Wit et al., 
 <xref rid="CIT0016" ref-type="bibr">2016</xref>; Guarner, 
 <xref rid="CIT0033" ref-type="bibr">2020</xref>). Conventional drug development methods take years and costly, offering more time for transmission of pathogens. The appropriate and timely development of potent antiviral agents for clinical use is of central interest, using cost-effective and fast computational approaches. Moreover, the approved pharmaceutical drugs may be repurposed as alternative method to screen for rapid identification of potential leads (Chu et al., 2006; Enayatkhani et al., 
 <xref rid="CIT0025" ref-type="bibr">2020</xref>; Muralidharan et al., 
 <xref rid="CIT0052" ref-type="bibr">2020</xref>; Pillaiyar et al., 2016; Yang et al., 
 <xref rid="CIT0074" ref-type="bibr">2005</xref>). In this regard, recently a large number of in-silico studies have been performed on medicinal plants, drug designing, and vaccine development (Aanouz et al., 
 <xref rid="CIT0001" ref-type="bibr">2020</xref>; Elfiky, 
 <xref rid="CIT0021" ref-type="bibr">2020a</xref>, 
 <xref rid="CIT0022" ref-type="bibr">2020b</xref>; Elfiky &amp; Azzam, 
 <xref rid="CIT0023" ref-type="bibr">2020</xref>; Elmezayen et al., 
 <xref rid="CIT0024" ref-type="bibr">2020</xref>; Enmozhi et al., 
 <xref rid="CIT0026" ref-type="bibr">2020</xref>; Joshi et al., 
 <xref rid="CIT0040" ref-type="bibr">2020</xref>; Pant et al., 
 <xref rid="CIT0054" ref-type="bibr">2020</xref>).
</p>
